Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1

Colin LaMont,Jakub Otwinowski,Kanika Vanshylla,Henning Gruell,Florian Klein,Armita Nourmohammad

DOI: https://doi.org/10.48550/arXiv.2112.00069

2021-12-01

Abstract:Broadly neutralizing antibodies (bNAbs) are promising targets for vaccination and therapy against HIV. Passive infusions of bNAbs have shown promise in clinical trials as a potential alternative for anti-retroviral therapy. A key challenge for the potential clinical application of bnAbs is the suppression of viral escape, which is more effectively achieved with a combination of bNAbs. However, identifying an optimal bNAb cocktail is combinatorially complex. Here, we propose a computational approach to predict the efficacy of a bNAb therapy trial based on the population genetics of HIV escape, which we parametrize using high-throughput HIV sequence data from a cohort of untreated bNAb-naive patients. By quantifying the mutational target size and the fitness cost of HIV-1 escape from bNAbs, we reliably predict the distribution of rebound times in three clinical trials. Importantly, we show that early rebounds are dominated by the pre-treatment standing variation of HIV-1 populations, rather than spontaneous mutations during treatment. Lastly, we show that a cocktail of three bNAbs is necessary to suppress the chances of viral escape below 1%, and we predict the optimal composition of such a bNAb cocktail. Our results offer a rational design for bNAb therapy against HIV-1, and more generally show how genetic data could be used to predict treatment outcomes and design new approaches to pathogenic control.

Populations and Evolution

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to design an optimal combination therapy of broadly neutralizing antibodies (bNAbs) to inhibit HIV - 1. Specifically, the paper focuses on the following aspects:

1. **Inhibition of virus escape**: Monotherapy (using a single bNAb) has shown certain clinical efficacy, but virus escape remains a major problem. The paper proposes to more effectively inhibit virus escape by combining multiple bNAbs.

2. **Prediction of treatment efficacy**: The paper has developed a computational method to predict the efficacy of bNAb therapy based on HIV population genetics data. This method uses high - throughput sequencing data to quantify the target size and fitness cost of HIV escape mutations, thereby predicting the distribution of virus rebound time.

3. **Optimization of combination therapy**: The paper not only predicts the efficacy of a single bNAb but also proposes how to select the optimal bNAb combination. The study found that a combination of three bNAbs can reduce the probability of virus escape to less than 1% and predicts the optimal composition of this combination.

### Overview of main content

#### 1. Introduction
- **Background**: Broadly neutralizing antibodies (bNAbs) show great potential in the prevention, treatment, and potential cure of rapidly evolving viruses such as HIV - 1.
- **Challenge**: Virus escape is the main obstacle to the clinical application of bNAbs. Combination therapy can more effectively inhibit escape, but selecting the optimal combination is a complex combinatorial problem.

#### 2. Model
- **HIV response to treatment**: The paper established an individual - level stochastic model to describe the dynamic changes of HIV after bNAb treatment. The model considers the competition process between sensitive and resistant strains, as well as the birth, death, mutation, and neutralization events in these processes.
- **Key parameters**: The key parameters of the model include mutation target size, fitness cost, and neutralization rate. These parameters are inferred from high - throughput sequencing data.

#### 3. Results
- **Population genetics of HIV escape**: The study analyzed high - throughput longitudinal data from 11 antiretroviral - treatment - naive (ART - naive) and bNAb - naive patients to infer the neutral diversity, mutation target size, and fitness cost of HIV escape mutations.
- **Prediction of efficacy**: The model successfully predicted the virus rebound time distribution in multiple clinical trials, including monotherapy and combination therapy. In particular, the model accurately predicted the proportion of late - stage virus rebound, which is an important indicator for evaluating treatment efficacy.
- **Optimization of combination therapy**: The study found that a combination of three bNAbs can significantly reduce the risk of virus escape and predicted the optimal bNAb combination.

### Conclusion
By combining population genetics data and computational models, the paper provides a rational method for designing bNAb combination therapies to more effectively inhibit the escape of HIV - 1. This method is not only applicable to HIV - 1 but can also be extended to the treatment design of other rapidly evolving pathogens.